Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Voyager Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.voyagertherapeut...
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Alfred W. Sandrock, Jr., MD
Number Of Employees: 172
Enterprise Value: $104,016,969
PE Ratio: -2.76
Exchange/Ticker 1: NASDAQ:VYGR
Exchange/Ticker 2: N/A
Latest Market Cap: $171,693,504
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Nov 21, 2024
Deals
Still seeking smaller bolt-ons, Novartis takes out gene therapy play Kate
Deal for up to $1.1B with ‘significant upfront payment’ rewards syndicate including Westlake and Versant, gives pharma three preclinical programs for muscular dystrophies
BioCentury | Sep 10, 2024
Deals
Deals report: Roivant sets up Pulmovant to advance hypertension therapy
Plus: Candid joining two VC-backed start-ups to focus on autoimmune bispecifics, and updates from Eli Lilly, Haya, Genetic Leap and more
BioCentury | Sep 4, 2024
Management Tracks
New CBOs at Stoke, Scholar Rock
Plus: Oppenheimer promotes Margolis; Biofidelity and Annexon each announce trio of hires; and Aura gets a new SVP
BioCentury | Jul 3, 2024
Management Tracks
CSO Kilty replaces Weir as Sitryx CEO
Plus: Y-mAbs hires Peter Pfreundschuh as CFO, and updates from LIfT,
BioCentury | Jun 14, 2024
Management Tracks
Connect leans into its U.S. profile as it remakes its leadership
Plus: Medivation vet Hung now chair of T-Therapeutics and updates from Voyager and Eyenuk
BioCentury | May 18, 2024
Discovery & Translation
Brain-penetrant AAV capsid progress at ASGCT
Companies and academics showcase two approaches to make AAV capsids with enhanced brain targeting and suppressed liver targeting
BioCentury | May 15, 2024
Discovery & Translation
Voyager’s journey to identify a new shuttle for bringing gene therapies into the brain
Biotech identifies ALPL as a cross-species cell surface receptor mediating BBB crossing of AAV capsid family
BioCentury | Apr 3, 2024
Management Tracks
Takeda vet Tanigaki named CEO of Aculys
Plus: Lonza names Wolfgang Wienand CEO, and updates from Verily, GSK, NewAmsterdam, Voyager, Adaptive, Ratio, Adlai Nortye and I-Mab
BioCentury | Apr 2, 2024
Product Development
Vectorized biologics: are patients and payers ready to swap biologics for gene therapies?
Gene therapy vectors that deliver biologic drugs enter late-state clinical trials
Items per page:
1 - 10 of 124